EIF5A and AL amyloidosis: SNS01-T, a nanoparticle containing an eIF5AK50R expression plasmid and an eIF5A1 siRNA, is currently being evaluated in a clinical trial in patients with advanced multiple myeloma [http://www.clinicaltrials.gov; Identifier: NCT01435720].